We observed that carriers of at least one <i>COMT</i> rs165815 C allele had lower odds for developing visual hallucinations (OR = 0.34; 95% CI = 0.16-0.72; <i>p</i> = 0.004), while carriers of at least one <i>DRD3</i> rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR = 1.88; 95% CI = 1.00-3.54; <i>p</i> = 0.049 and OR = 3.31; 95% CI = 1.37-8.03; <i>p</i> = 0.008, respectively).
We observed that carriers of at least one <i>COMT</i> rs165815 C allele had lower odds for developing visual hallucinations (OR = 0.34; 95% CI = 0.16-0.72; <i>p</i> = 0.004), while carriers of at least one <i>DRD3</i> rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR = 1.88; 95% CI = 1.00-3.54; <i>p</i> = 0.049 and OR = 3.31; 95% CI = 1.37-8.03; <i>p</i> = 0.008, respectively).
The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020).
The G2019S mutation carriers showed a non significant increase in dyskinesias, and 2/3 developed Dopamine Dysregulation Syndrome and visual hallucinations.
The authors conducted a case-control study of Parkinson's disease patients with and without visual hallucinations to investigate associations of the polymorphisms of the dopamine receptors D2 32806 C>T (Taq1A), D3 Ser9Gly and Msp1, D5 978T>C and dopamine transporter 3'-UTR 40 bp VNTR with visual hallucinations in Parkinson's disease.